Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21920713 | 0.88 | KDM4E (0.41) | ALOX5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL12814114 | 0.76 | PARP1 (0.43) | ALOX5ALDH1A1PARP1 | |
| SCHEMBL14659998 | 0.69 | HSD17B10 (0.37) | ALOX5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3701968 | 0.65 | KDM4E (0.44) | ALOX5KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL34469245 | 0.64 | CHRNB2 (0.42) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL9361934 | 0.63 | KDM4E (0.53) | KDM4EALDH1A1HPGDHSD17B10PARP1 | |
| SCHEMBL17375194 | 0.62 | KDM4E (0.37) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL4299251 | 0.62 | — | — | |
| SCHEMBL15196098 | 0.62 | — | — | |
| SCHEMBL22675658 | 0.62 | CYBB (0.38) | KDM4EALDH1A1HSD17B10MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3994133-A1 | HPK1 INHIBITORS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021000935-A1 | HPK1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | ALOX5 3696/4885KDM4E 2717/4885ALDH1A1 3619/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | ALOX5 4368/4885KDM4E 3080/4885ALDH1A1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.